標題: Titlebook: Cardiac Arrhythmias: New Therapeutic Drugs and Devices; Proceedings of the S Joel Morganroth,E. Neil Moore Conference proceedings 1985 Mart [打印本頁] 作者: Malnutrition 時間: 2025-3-21 16:39
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices影響因子(影響力)
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices影響因子(影響力)學(xué)科排名
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices網(wǎng)絡(luò)公開度
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices被引頻次
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices被引頻次學(xué)科排名
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices年度引用
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices年度引用學(xué)科排名
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices讀者反饋
書目名稱Cardiac Arrhythmias: New Therapeutic Drugs and Devices讀者反饋學(xué)科排名
作者: Subjugate 時間: 2025-3-21 23:23 作者: 溫室 時間: 2025-3-22 01:49 作者: Locale 時間: 2025-3-22 05:24 作者: Estrogen 時間: 2025-3-22 12:41
https://doi.org/10.1007/b138648units. and from chance events captured on dynamic ECG recorders. show that ventricular tachyarrhythmias (ventricular tachycardia, ventricular flutter and ventricular fibrillation) are the commonest arrhythmias implicated.作者: modifier 時間: 2025-3-22 14:20 作者: modifier 時間: 2025-3-22 18:20
Conservation Laws and Shock Waves,The clinical reviewer for New Drug Applications (NDA) or Investigational New Drug Exemptions (IND’s) is faced with the sheer weight of the applications and NDA submissions have gone well above 1,000 volumes in size. Since each volume is about 500 pages long, this is about one half million pages to review.作者: stroke 時間: 2025-3-22 22:34 作者: AMPLE 時間: 2025-3-23 05:01
Use of a Computer in the New Drug Evaluation ProcessThe clinical reviewer for New Drug Applications (NDA) or Investigational New Drug Exemptions (IND’s) is faced with the sheer weight of the applications and NDA submissions have gone well above 1,000 volumes in size. Since each volume is about 500 pages long, this is about one half million pages to review.作者: 鈍劍 時間: 2025-3-23 06:16 作者: 側(cè)面左右 時間: 2025-3-23 10:51 作者: 細菌等 時間: 2025-3-23 15:57 作者: prodrome 時間: 2025-3-23 18:08 作者: Tailor 時間: 2025-3-24 00:26 作者: ACME 時間: 2025-3-24 03:19
https://doi.org/10.1007/b138648ties, their electrophysiologic properties in the intact heart (where studies could determine thresholds of conduction), and their clinical use in specific syndromes. Most of these attempts did not increase our knowledge of antiarrhythmic drugs or their clinical application. Since quinidine, introduc作者: electrolyte 時間: 2025-3-24 09:05 作者: 恃強凌弱 時間: 2025-3-24 11:42
Linear Partial Differential Equations,esults in impaired conduction velocity in myocardial tissue.. Overall clinical antiarrhythmic efficacy in this group is dependent upon the ability of these agents to alter conduction and refractoriness, and suppress diastolic depolarization, thereby interfering with reentrant circuits and suppressin作者: 精確 時間: 2025-3-24 18:15
Conservation Laws and Shock Waves,ysfunction can be identified as being at high risk for sudden cardiac death, protocols have been implemented to determine whether this endpoint can be eliminated. The group of antiarrhythmic agents, which are known as Vaughan Williams Class IC agents have demonstrated particularly unique clinical ch作者: 葡萄糖 時間: 2025-3-24 21:47
Linear Partial Differential Equations,lethal ventricular arrhythmias without hemodynamical 1 y significant symptoms1 the most appropriate endpoint of drug efficacy should be the prevention of sudden cardiac death. The pharmacological endpoint of significant statistical reduction in ventricular ectopic frequency, however, has been the mo作者: 鐵砧 時間: 2025-3-24 23:37
Linear Partial Differential Equations,In addition to their pharmacologic property of prolonging myocardial repolarization they were all introduced for clinical use and study for indications unrelated to cardiac arrhythmias. Therefore, it is important to remember that their development was not guided by the intention to develop an ideal 作者: 木訥 時間: 2025-3-25 05:14
Nonlinear Diffusion-Reaction Phenomena,in much the same way as it might be used in medical practice. A design and analysis which parallel the expected clinical use of the drug might be seen as lessening the problems of extrapolation which so often arise after a clinical trial is completed. However, this desire to mimic clinical practice 作者: 止痛藥 時間: 2025-3-25 07:50 作者: 自戀 時間: 2025-3-25 15:20 作者: magnate 時間: 2025-3-25 18:07
Conservation Laws and Shock Waves,brillation (VF). Routine clinical evaluation usually reveals ample evidence for the existence of heart disease in patients with these arrhythmias. Coronary heart disease is by far the most frequently occurring etiologic form of heart disease (about 80%) followed by cardiomyopathy and valvular heart 作者: Visual-Field 時間: 2025-3-25 21:25 作者: 畏縮 時間: 2025-3-26 02:17
0166-9842 pends upon precisely what question is being asked. The large number of experimental models used to evaluate antiarrhythmic compounds points out the inability of anyone model to define the probability of antiarrhythmic efficacy in man. It has therefore become standard practice to utilize a batter of 作者: Demonstrate 時間: 2025-3-26 06:50 作者: 不易燃 時間: 2025-3-26 09:29 作者: 過分 時間: 2025-3-26 14:34 作者: 逗它小傻瓜 時間: 2025-3-26 19:19
What Animal Models are Useful in Selecting New Antiarrhythmic Drugs?ening” for a new active compound or alternatively, “evaluating” an already identified active antiarrhythmic drug. This paper will deal primarily with models designed to evaluate mechanisms of action and effectiveness of new antiarrhythmic agents.作者: machination 時間: 2025-3-26 21:40 作者: collagenase 時間: 2025-3-27 01:13
Status of Class III Antiarrhythmic Drugs: Amiodarone, Bretylium and Sotalols unrelated to cardiac arrhythmias. Therefore, it is important to remember that their development was not guided by the intention to develop an ideal antiarrhythmic agent. As Dr. Vaughan Williams has said :作者: 藕床生厭倦 時間: 2025-3-27 08:36
Sudden Death as an End-Point for the Clinical Evaluation of Antiarrhythmic Drugs a subsequent reduction in the risk of dysrhythmic deaths. Thus, it is appropriate to consider whether sudden death can be adequately identified as a dysrhythmic event so that it can be used as an end-point for a clinical trial evaluating antiarrhthymic agents.作者: 急急忙忙 時間: 2025-3-27 09:25 作者: 古董 時間: 2025-3-27 17:22 作者: Ptosis 時間: 2025-3-27 18:12
Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — Efficacy in the Treatment of Ventricutoriness, depressing membrane excitability, membrane responsiveness, and automaticity in normal Purkinje fibers.. The current status of cibenzoline and pirmenol, two investigational agents for the treatment of ventricular rhythm disturbances, are also reviewed. Both these drugs share many electrophysiologic properties with the Type IA drugs.作者: VALID 時間: 2025-3-27 23:12
Holter/Exercise and Electrophysiologic Methods for Evaluating Drug Therapy for Malignant Ventricularluding runs of unsustained VT. When antiarrhythmic drug treatment is stopped, electrophysiologic studies are capable of inducing sustained VT or VF in about 80% of those who present with recurrent sustained VT as the clinical arrhythmia and in about 70% of those who had a cardiac arrest and were found in VF (1–4).作者: 新娘 時間: 2025-3-28 04:21
https://doi.org/10.1007/978-0-8176-8265-1 a subsequent reduction in the risk of dysrhythmic deaths. Thus, it is appropriate to consider whether sudden death can be adequately identified as a dysrhythmic event so that it can be used as an end-point for a clinical trial evaluating antiarrhthymic agents.作者: interrupt 時間: 2025-3-28 08:25 作者: 逗留 時間: 2025-3-28 13:06
Initial Evaluation of New Antiarrhythmic Agents in Man: Normal Volunteers or Patients? of new chemical entities has evolved which attempts to maximize safety and protect the patient/volunteer. Under the usual scheme of things, following extensive toxicological evaluation in animals, a candidate drug is administered to apparently healthy human subjects, most often young adult males, i作者: Fatten 時間: 2025-3-28 16:23
Is There a Rational Basis for the Modified Classification of Antiarrhythmic Drugs?ties, their electrophysiologic properties in the intact heart (where studies could determine thresholds of conduction), and their clinical use in specific syndromes. Most of these attempts did not increase our knowledge of antiarrhythmic drugs or their clinical application. Since quinidine, introduc作者: monogamy 時間: 2025-3-28 21:42 作者: 廚房里面 時間: 2025-3-29 01:26
Mexiletine, Tocainide and Ethmozine: Newer Class I Antiarryhthmic Agentsesults in impaired conduction velocity in myocardial tissue.. Overall clinical antiarrhythmic efficacy in this group is dependent upon the ability of these agents to alter conduction and refractoriness, and suppress diastolic depolarization, thereby interfering with reentrant circuits and suppressin作者: Servile 時間: 2025-3-29 06:33
Class IC Antiarrhythmic Agents: Status — 1984ysfunction can be identified as being at high risk for sudden cardiac death, protocols have been implemented to determine whether this endpoint can be eliminated. The group of antiarrhythmic agents, which are known as Vaughan Williams Class IC agents have demonstrated particularly unique clinical ch作者: 釘牢 時間: 2025-3-29 09:34 作者: Pudendal-Nerve 時間: 2025-3-29 12:26
Status of Class III Antiarrhythmic Drugs: Amiodarone, Bretylium and SotalolIn addition to their pharmacologic property of prolonging myocardial repolarization they were all introduced for clinical use and study for indications unrelated to cardiac arrhythmias. Therefore, it is important to remember that their development was not guided by the intention to develop an ideal 作者: apiary 時間: 2025-3-29 18:05 作者: Spinous-Process 時間: 2025-3-29 22:17
Sudden Cardiac Death — Failure or Effect of Antiarrhythmic Drug Therapy?units. and from chance events captured on dynamic ECG recorders. show that ventricular tachyarrhythmias (ventricular tachycardia, ventricular flutter and ventricular fibrillation) are the commonest arrhythmias implicated.作者: Promotion 時間: 2025-3-30 03:23
Sudden Death as an End-Point for the Clinical Evaluation of Antiarrhythmic Drugshythmia induced death rather than alleviating symptomatology. The major dilemma facing the clinician is that the use of easily quantifiable total or partial pharmacologic suppression of ventricular arrhythmia during a period of electrocardiographic monitoring has not been shown to be associated with作者: 設(shè)施 時間: 2025-3-30 06:43
Holter/Exercise and Electrophysiologic Methods for Evaluating Drug Therapy for Malignant Ventricularbrillation (VF). Routine clinical evaluation usually reveals ample evidence for the existence of heart disease in patients with these arrhythmias. Coronary heart disease is by far the most frequently occurring etiologic form of heart disease (about 80%) followed by cardiomyopathy and valvular heart 作者: aqueduct 時間: 2025-3-30 10:23
Nonlinear Diffusion-Reaction Phenomena,s ratio is invariably tilted in the risk direction, however slightly, when a healthy subject takes part in a Phase I study of any chemical compound. Tolerance, if not related to therapeutic effect, has littile practical import. Why expose healthy volunteen to a test compound until adverse effect occ
